Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

Transmeta Corporation (TMTA)

5.364 Posts
Pagina: «« 1 ... 253 254 255 256 257 ... 269 »» | Laatste | Omlaag ↓
  2. [verwijderd] 23 februari 2006 22:26

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Maximaal! schreef:

    is het goed nieuws??

    schrijven ze niet dat 2006 ook een verliws jaar wordt??

    nabeurs zakt ook al weer,

    vr.gr. berry
    1.58
  4. [verwijderd] 23 februari 2006 22:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Transmeta's Full Year 2005 Revenue Increases 147% to $72.7 Million; Company Exceeds Fourth Quarter Financial Guidance

    E-mail | Print | | Disable live quotes Last Update: 4:05 PM ET Feb 23, 2006

    SANTA CLARA, Calif., Feb 23, 2006 (BUSINESS WIRE) -- Transmeta Corporation (TMTA : transmeta corp del com
    News , chart, profile, more
    Last: 1.45+0.10+7.41%

    4:13pm 02/23/2006
    Add to portfolio
    Analyst
    Create alertInsider
    Discuss
    Financials
    Sponsored by:
    TMTA1.45, +0.10, +7.4%) , the leader in efficient computing technologies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2005.
    Highlights for the 2005 Full Year
    -- Continued to execute a successful transformation of the Company's business model.
    -- Created and executed significant new service relationships with Sony and Microsoft.
    -- Completed technology transfer and recorded revenue from Fujitsu and Sony, our second and third licensees of our LongRun2 technologies.
    -- Revenue increased by 147% to $72.7 million compared to $29.4 million in 2004.
    -- License and service revenue of $48.1 million, a 351% increase, compared to $10.7 million for the 2004 full year.
    -- Net loss significantly reduced from $106.8 million to $6.2 million.
    -- Cash balance of $56.5 million at December 31, 2005, and no long-term debt.
    Business Update
    "2005 has been a year of significant achievement and excellent execution for Transmeta," commented Arthur L. Swift, president and CEO. "We more than doubled our revenue, cut our losses by roughly $100 million and won major new relationships with marquee partners such as Microsoft and Sony. Over the last two years, we've created significant new revenue streams from licensing and services that have already contributed substantially to our improved results. Our industry needs low power solutions, and we think that we are uniquely positioned with our innovative technologies and superb engineering talent."
    The Company reported total revenue of $72.7 million, a 147% increase, compared to $29.4 million for the 2004 full year. License and service revenue was $48.1 million, a 351% increase, compared to $10.7 million for the 2004 full year. As a result of Transmeta's modified business model, the Company reported a significantly reduced net loss of $6.2 million, or $0.03 per share in 2005 compared to a net loss of $106.8 million, or $0.61 per share for the 2004 full year. Included in the 2005 and 2004 results are restructuring and fixed asset impairment charges of $2.0 million and $3.4 million, respectively.
    Revenue for the fourth quarter of 2005 was $13.3 million, slightly ahead of the Company's previous guidance of between $12.0 and $13.0 million, compared to $11.2 million in the fourth quarter of 2004. Gross margin for the fourth quarter was 47.0% compared to a negative gross margin of 13.7% for the fourth quarter of 2004. The Company's net loss of $2.1 million, or a loss of $0.01 per share, for the fourth quarter of 2005 was better than the Company's earlier guidance of a net loss between $5.4 to $5.9 million. This is compared with a net loss of $28.1 million, or a loss of $0.15 per share, in the fourth quarter of 2004.
    The Company's cash, cash equivalents and short term investments at December 31, 2005 totaled $56.5 million, which was $3.5 million ahead of prior guidance. In addition, the Company ended the year with no long-term debt as it paid its remaining $5.0 million debt obligation to IBM in the fourth quarter of 2005, earlier than required by the agreement.
    "The substantial progress that we made in 2005 enabled us to enter 2006 in a much better financial condition with more strategic and financial flexibility versus this time last year," commented Mark R. Kent, chief financial officer. "Our stated and primary objective during the second half was to be break-even or better on a cash flow from operations basis. We clearly met this goal as we ended the second half with a positive cash flow from operations of $14.1 million. We were thus able to repay a $5.0 million obligation six months ahead of schedule, leaving us with no debt and $56.5 million in cash, higher than our earlier goal of $53.0 million."
    Guidance
    For 2006, the Company is anticipating:
    -- Full year revenue will be in the range of $60.0 to $72.0 million, substantially from licensing and services.
    -- Full year net loss of $18 million to $12 million, or a loss of $0.09 to $0.06 per share, which includes non-cash charges of $7 million of patent amortization and $5 million of stock option compensation expense.
    -- First half revenue of at least $27 million.
    -- First and second quarter revenue is in part dependent on the timing of the recognition of approximately $8.9 million of deferred revenue related to services performed in 2005.
    -- First half negative operating cash flow no more than $10 million, second half return to positive cash flow.
    "In contrast to a year ago, we enter 2006 with a much better business outlook," added Kent. "We have very good visibility into achieving most of the low-end of the revenue range based on expectations from our current customers, and we can achieve the full revenue range through already identified opportunities. Based on our current visibility we expect a loss for the year, but it is manageable while we build a business characterized by recurring revenue streams, which we expect to begin to realize later in 2006 and 2007."
  5. [verwijderd] 23 februari 2006 22:30

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    As previously announced, Transmeta's management will host a conference call at 5:00 p.m. Eastern time / 2:00 p.m. Pacific time. The conference call will be available live over the Internet at the investor relations section of Transmeta's website at www.transmeta.com. To listen to the conference call, please dial (913) 981-4915. A recording of the conference call will be available for one week, starting one hour after the completion of the call, until 9:59 p.m. Pacific time on March 2. The phone number to access the recording is (888) 203-1112, and the passcode is 7271974. For callers outside the U.S., please dial (719) 457-0820, with the same passcode.
    About Transmeta Corporation
    Transmeta Corporation develops and licenses innovative computing, microprocessor and semiconductor technologies and related intellectual property. Founded in 1995, Transmeta first became known for designing, developing and selling its highly efficient x86-compatible software-based microprocessors, which deliver a balance of low power consumption, high performance, low cost and small size suited for diverse computing platforms. We also develop advanced power management technologies for controlling leakage and increasing power efficiency in semiconductor and computing devices. To learn more about Transmeta, visit www.transmeta.com.
    Safe Harbor Statement
    This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements speak only as of the date of this release, and we will not necessarily provide updates of our projections or other forward-looking statements. Investors are cautioned that such forward-looking statements are subject to many risks and uncertainties, and may differ materially or adversely from our actual results or future events. Important risk factors that could have material or adverse effects on our results include general economic and political conditions, specific conditions and volatility in the markets that we address, the potential loss of key technical and business personnel, practical challenges in modifying our business model, our ability to satisfy the continued listing requirements of the Nasdaq Stock Market, the adoption and market acceptance of our products and technologies by current and potential customers and licensees, our inability to predict or ensure that third parties will license our technologies or use our technologies to generate royalties, the rescheduling or cancellation of significant customer orders, difficulties in developing or manufacturing our products in a timely and cost effective manner, our dependence on third parties for sourcing materials and providing manufacturing services, intense competition and competitive pressures, the ability to enter strategic collaborations or raise financing on satisfactory terms, patents and other intellectual property rights, and other risk factors. We urge investors to review our filings with the Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-K/A, 10-Q and 8-K, which describe these and other important risk factors that could have an adverse effect on our results. We undertake no obligation to revise or update publicly any forward-looking statement for any reason.
    Transmeta is a trademark of Transmeta Corporation. All other product or service names mentioned herein are the trademarks of their respective owners.
    Transmeta Corporation
    Condensed Consolidated Balance Sheets
    (in thousands)

    December 31, December 31,
    2005 2004 (1)
    ------------- ------------

    ASSETS
    Current assets:
    Cash and cash equivalents $ 27,659 $ 17,273
    Short-term investments 28,811 36,395
    Accounts receivable, net 1,686 2,290
    Inventories 265 5,410
    Prepaid and other current assets 2,279 2,218
    ------------- ----------
    Total current assets 60,700 63,586

    Property, plant and equipment, net 1,623 2,187
    Patents and patent rights, net 16,080 22,926
    Other assets 911 914
    ------------- ----------
    TOTAL ASSETS $ 79,314 $ 89,613
    ============= ==========

    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current Liabilities:
    Accounts payable $ 1,521 $ 6,224
    Accrued compensation and benefits 3,279 4,189
    Accrued inventory-related charges - 4,876
    Deferred income, net 5,937 29
    Accrued other 2,109 5,694
    Advances from customers 7,260 -
    Accrued restructuring costs 1,803 1,557
    Current portion of long-term debt - 356
    ------------- ----------
    Total current liabilities 21,909 22,925

    Long-term accrued restructuring costs 2,453 3,688
    Long-term payables, net of current portion - 5,000

    Stockholders' equity:
    Common stock 713,129 709,926
    Treasury stock (2,439) (2,439)
    Accumulated other comprehensive loss (195) (125)
    Accumulated deficit (655,543) (649,362)
    ------------- ----------
    Total stockholders' equity 54,952 58,000
    ------------ ---------
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 79,314 $ 89,613
    ============= ==========

    (1) Derived from the Company's audited financial statements as of
    December 31, 2004, included in the Company's Form 10-K filed with
    the Securities and Exchange Commission.

    TRANSMETA CORPORATION
    CONSOLIDATED STATEMENTS OF OPERATIONS
    (Dollars in thousands, except per share data)
    (Unaudited)

    Three Months Ended Twelve Months Ended
    ----------------------------------------
    December December December December
    31, 31, 31, 31,
    2005 2004 2005 2004
    --------- --------- --------- ----------

    Revenue:
    Product $ 3,235 $ 4,799 $ 24,636 $ 18,776
    License - 6,000 19,628 9,000
    Service 10,077 448 28,467 1,668
    --------- --------- --------- ----------
    Total revenue
  6. [verwijderd] 23 februari 2006 22:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Three Months Ended Twelve Months Ended
    ----------------------------------------
    December December December December
    31, 31, 31, 31,
    2005 2004 2005 2004
    --------- --------- --------- ----------

    Revenue:
    Product $ 3,235 $ 4,799 $ 24,636 $ 18,776
    License - 6,000 19,628 9,000
    Service 10,077 448 28,467 1,668
    --------- --------- --------- ----------
    Total revenue 13,312 11,247 72,731 29,444
    --------- --------- --------- ----------

    Cost of revenue
    Product 1,402 10,654 12,271 36,335
    License - - 71 -
    Service 5,660 189 15,990 730
    Impairment charge on long-
    live assets - 1,943 - 1,943
    --------- --------- --------- ----------
    Total cost of revenue 7,062 12,786 28,332 39,008
    --------- --------- --------- ----------
    Gross profit (loss) 6,250 (1,539) 44,399 (9,564)

    Operating expenses:
    Research and development 2,491 12,578 19,609 52,765
    Selling, general and
    administrative 5,564 9,292 23,039 30,855
    Restructuring charges (875) - 2,009 904
    Amortization of intangible
    assets 1,713 2,233 6,846 9,217
    Impairment charge on long-
    lived and other assets - 2,544 - 2,544
    Stock compensation 14 29 (34) 1,665
    --------- --------- --------- ----------
    Total operating expenses 8,907 26,676 51,469 97,950
    --------- --------- --------- ----------
    Operating loss (2,657) (28,215) (7,070) (107,514)
    Interest income and other,
    net 609 150 1,253 827
    Interest expense (18) (50) (364) (111)
    --------- --------- --------- ----------
    Net loss $ (2,066) $(28,115) $ (6,181) $(106,798)
    ========= ========= ========= ==========

    Net loss per share - basic
    and fully diluted $ (0.01) $ (0.15) $ (0.03) $ (0.61)
    ========= ========= ========= ==========

    Weighted average shares
    outstanding - basic and
    fully diluted 191,649 182,104 190,404 175,989

  7. [verwijderd] 23 februari 2006 22:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    SAN FRANCISCO (MarketWatch) -- Transmeta Corp. (TMTA : transmeta corp del com
    News , chart, profile, more
    Last: 1.45+0.10+7.41%

    TMTA1.45, +0.10, +7.4%) shares were trading up 5% at $1.52 after the closing bell on Thursday. Transmeta reported a fourth-quarter net loss of $2.1 million, or a penny a share, compared with a net loss of $28.1 million, or 15 cents a share, during the year-ago period. The Santa Clara, Calif.-based developer of computing, microprocessor and semiconductor technologies posted revenue of $13.3 million vs. $11.2 million a year ago. Two analysts polled by Thomson First Call had forecast a fourth-quarter loss of 4 cents a share on revenue of $12 million. For 2006, Transmeta expects a net loss of $12 million to $18 million, or 6 cents to 9 cents a share, on revenue of $60 million to $72 million. The company sees first-half revenue of at least $27 million. Analysts are currently looking for a per-share loss of a penny on revenue of $64 million for the year
  9. gustaaf1e 23 februari 2006 22:38

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 04 mrt 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    quote:

    Maximaal! schreef:

    is het goed nieuws??

    schrijven ze niet dat 2006 ook een verliws jaar wordt??

    nabeurs zakt ook al weer,

    vr.gr. berry
    EPS 2004 was $-0,61. Over 2005 $-0,03.
    Lijkt me goed nieuws.
    Ze schrijven dat winst in 2006 of 2007 komt.
    Zal in cc worden toegelicht. Hangt natuurlijk af van licentie- en andere inkomsten die niet op voorhand met zekerheid zijn aan te geven.
    G
  10. [verwijderd] 23 februari 2006 22:46

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik zie inderdaad ook het volgende:
    Opbrengs omzet, en winst word volgens mij een beetje door elkaar gegooid door de beleggers, we zullen weer gaan zakken.

    For 2006, the Company is anticipating:
    -- Full year revenue will be in the range of $60.0 to $72.0 million, substantially from licensing and services.
    -- Full year net loss of $18 million to $12 million, or a loss of $0.09 to $0.06 per share, which includes non-cash charges of $7 million of patent amortization and $5 million of stock option compensation expense.
    -- First half revenue of at least $27 million.
    -- First and second quarter revenue is in part dependent on the timing of the recognition of approximately $8.9 million of deferred revenue related to services performed in 2005.
    -- First half negative operating cash flow no more than $10 million, second half return to positive cash flow.

    Maar die 5 + 7 miljoen zijn lijkt mij eenmalige kosten.
    Patenten en stock option compensation

    - Full year revenue will be in the range of $60.0 to $72.0 million
    -Full year net loss of $18 million to $12 million,

    Dat rijmt toch niet met elkaar? of wel. Moet dat revenue niet turnover zijn?

  14. [verwijderd] 24 februari 2006 07:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    baal als een stekker schreef:

    De koers staat AH wel flink hoger, maar ik denk niet dat er veel met de koers zal gebeuren morgen.
    m.v.g.Willem
    na een dag volume van 4 mijl
  15. positivo73 24 februari 2006 09:51

    • positivo73

      Lid sinds: 25 mrt 2004

      Laatste bezoek: 03 mei 2023

    • Aanbevelingen

      Ontvangen: 370

      Gegeven: 163

    •    Aantal posts: 6.036

    quote:

    voiceless schreef:

    Waarom niet?
    Ik dacht dat, omdat ik het pb vluchtig door had gelezen en niet goed. Ik heb het pb net nog een keer doorgelezen en zover ik het kan begrijpen ziet het er wel dgelijk goed uit. Volgens mij is Q4 ook meegevallen.Ik denk dat TMTA vandaag wel flink omhoog gaat.
    m.v.g.Willem
  17. [verwijderd] 24 februari 2006 09:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Pump_up_the_Volume_ schreef:

    De zittenblijvers zullen vandaag rijkelijk beloond worden.
    Dank voor de steun, Pump.

    Psycho
    as always: zittenblijver
  18. [verwijderd] 24 februari 2006 11:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    waar zal de top liggen denken jullie?
    En zou hij de komende maanden verder gaan stijgen, of
    weer langzaam afdalen naar rond de 1,40

    Ik zit er nu nog in, maar ben vorrige keer niet vergeten.
    Toen stond hij opeens ook weer op 1,20.
  21. [verwijderd] 24 februari 2006 12:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    psycho-pharma schreef:

    [quote=Pump_up_the_Volume_]
    De zittenblijvers zullen vandaag rijkelijk beloond worden.
    [/quote]

    Dank voor de steun, Pump.

    Psycho
    as always: zittenblijver
    Arak,

    Ook zittenblijver, en hoopt nu op een beetje mazzel
5.364 Posts
Pagina: «« 1 ... 253 254 255 256 257 ... 269 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.076
AB InBev 2 5.521
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.752
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.755
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.754
Aedifica 3 919
Aegon 3.258 322.893
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.895
Agfa-Gevaert 14 2.051
Ahold 3.538 74.342
Air France - KLM 1.025 35.087
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.936
Allfunds Group 4 1.502
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.823
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.404
AMG 971 133.739
AMS 3 73
Amsterdam Commodities 305 6.697
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.017
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.786
Arcelor Mittal 2.034 320.776
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.315
ASML 1.766 108.234
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 515
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.688
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.404